Non-ergot dopamine receptor agonist. Prepn and activity of enantiomers: W. Timmerman et al., Eur. J. Pharmacol. 166, 1 (1989) DOI PubMed. Improved synthesis: G. Minaskanian, K. Rippel, US 6372920 (2002 to Aderis). Clinical trial of transdermal formulation in early Parkinson's disease: R. L. Watts et al., Neurology 68, 272 (2007) DOI PubMed. Review of pharmacology and clinical experience of transdermal formulation in Parkinson's disease: Y. Naidu, K. Ray Chaudhuri, Expert Opin. Drug Deliv. 4, 111-118 (2007) DOI PubMed; and in restless legs syndrome: M. Y. Splinter, Ann. Pharmacother. 41, 285-295 (2007) DOI PubMed.
Determn of enantiomeric purity by chiral HPLC: D. T. Witte et al., Chirality 4, 62 (1992) DOI. GC/MS determn in plasma: P. A. Zavitsanos et al., Rapid Commun. Mass Spectrom. 7, 1145 (1993) DOI PubMed.
Prepn: A. S. Horn, US 4564628 (1986 to Nelson).
Antiparkinsonian.
Dopamine Receptor Agonist